Join ACC's Prevention of Cardiovascular Disease Member Section this Wednesday, April 9 at 1 p.m. ET for a recap of ACC.25 prevention content and its influence on clinical practice. The webinar will ...

A 21-year-old male collegiate football player presents for an annual physical examination with blood pressure (BP) elevated to 147/82 mm Hg. He is counseled on lifestyle modifications, including the ...

An artificial intelligence (AI) model trained to detect blocked coronary arteries based on electrocardiogram (ECG) readings performed better than expert clinicians and was on par with troponin T ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

"Refocusing and reframing the definition and discussion of coronary artery disease (CAD) from late-stage ischemia and acute coronary events to early detection of coronary artery atheroma and ...

AZD0780, a novel, once-daily oral molecule inhibitor, had a robust, dose-dependent effect in lowering LDL-C and a favorable safety profile in patients with hypercholesterolemia already on background ...

The ZENITH trial demonstrated that among high-risk adults with PAH on maximum tolerated dose of background therapy, treatment with sotatercept resulted in a lower risk of all-cause death, lung ...

Coronary atherosclerotic phenotypes, including total plaque volume (TPV), noncalcified plaque (NCP), calcified plaque (CP) and percentage atheroma volume (PAV), assessed by artificial ...

Angiopoietin-like 3 (ANGPTL-3) inhibition with the human monoclonal antibody, SHR-1918, reduces serum LDL-C by 22% to 30%, as well as triglyceride (TG) levels by 52% to 63%, in patients at moderate or ...

The HERZCHECK trial demonstrates the feasibility and diagnostic value of a mobile, CMR-based screening strategy for detecting asymptomatic stage B HF in rural, high-risk populations. Participants in ...

Solbinsiran at the 400 mg dose reduced apolipoprotein B (apoB) concentration in patients with mixed dyslipidemia, according to research presented during a Featured Clinical Research session at ACC.25 ...

Intravenous (IV) iron supplementation with ferric carboxymaltose was found to be well tolerated and improve quality of life in patients with heart failure with reduced ejection fraction (HFrEF) and ...